Dormant Breast Cancer Cells Hidden Behind Protective Shields: New Tumor Maps Explain Why Cancer Returns After Treatment

New research published in Genome Medicine has produced the most detailed maps yet of breast cancer tumors — and uncovered hidden pockets of dormant breast cancer cells hiding behind protective “shields” that may help explain why breast cancer returns after treatment. The findings, from scientists at the MRC Laboratory of Medical Sciences (LMS), Imperial College London and the UCL Genetics Institute, suggest that future breast cancer therapies may need to target slow-hiding cells — not just fast-growing ones — to prevent tumor relapse.

What the new breast cancer study found

The international team built detailed cellular maps of untreated breast tumors and discovered that tumors contain two very different neighbourhoods:

• Regions of actively dividing cancer cells — the fast-growing cells that most chemotherapy is designed to kill.
• Distinct clusters of dormant (quiescent) cancer cells — quiet cells that have essentially put their growth on hold and can survive treatment.

Strikingly, the dormant cells were frequently wrapped in immune cells (CXCL10-positive macrophages) and tumor-supporting connective tissue cells (myofibroblastic cancer-associated fibroblasts) that appear to act as a protective barrier — the “shields” described by the researchers.

Why dormant breast cancer cells are dangerous

“Quiescent cancer cells are very dangerous,” said Dr Alexis Barr, co-lead author and head of the Cell Cycle Control group at the MRC LMS. “These cells can hide from chemotherapy and then remain in this dormant quiescent state in the tumor, and then later reactivate to drive proliferation.”

Cancer cells can enter this hibernation-like state when a growing tumor outstrips its blood supply and nutrients become scarce. Much like a bear hibernating through winter, the cells sit inactive until conditions improve — which may only happen once treatment has finished.

“If we want to achieve long-term control of people’s tumors and prevent tumor relapse, we have to focus on these dormant quiescent cancer cells, and have to understand more about them,” Dr Barr added.

Mapping the tumor, cell by cell

To locate these hidden populations, the researchers combined two cutting-edge techniques:

• Single-cell RNA sequencing, which reveals which genes each individual cell is using.
• Spatial transcriptomics, which shows where those cells sit within the tumor and which cells surround them.

The analysis, led with Dr Maria Secrier’s computational biology team at UCL, produced an unexpected result: cells resembling therapy-resistant cells were already present in tumors before any treatment had been given — and this pattern appeared in both aggressive and slower-growing forms of breast cancer, even though dormancy had previously been linked mainly with slower-progressing disease.

The “protective shields” around dormant cells

“The cancer cells are really encapsulated within these areas of macrophages and fibroblasts that we think act as shields for these dormant cancer cells,” said Dr Secrier. She noted that the cause-and-effect direction is still unknown: surrounding cells may push cancer cells into dormancy, or cancer cells may actively attract and remodel their surroundings — “It’s very likely coming from both sides.”

The team also detected increased activity in the complement pathway, part of the immune system, within the dormant cell niches — raising the possibility that drugs targeting this pathway could make those protected areas more vulnerable.

What this means for future breast cancer treatment

Many chemotherapy drugs work best against rapidly dividing cells, which is precisely why dormant cells are so hard to eliminate. The findings imply that different regions of the same tumor may respond to different drugs:

• Fast-growing regions may respond to conventional chemotherapy.
• Dormant, shielded regions may need therapies directed at the sleeping cells themselves, the surrounding “shield” cells, or immune pathways such as complement.

“Different parts of the tumor will likely respond to different drugs,” said Dr Secrier. “If we understand what drug combinations we can use to target both the proliferative and the dormant areas, potentially that could be more successful than current therapies.”

Study limitations and next steps

This is fundamental research, not a new treatment — no clinical recommendations change today. Key open questions remain: whether the surrounding cells truly maintain dormancy, how important they are to cancer cell survival, and which drug combinations could safely target both tumor regions. The team says the maps offer “a first insight” into how future therapies could be tailored to different areas of a tumor where cells have adapted and evolved differently.

Frequently asked questions

What are dormant breast cancer cells?

Dormant (quiescent) cancer cells are cancer cells that have stopped dividing and entered a resting state. They can survive chemotherapy, remain hidden in the tumor, and later reactivate to drive cancer growth or return.

Why does breast cancer come back after treatment?

One leading explanation is that some cancer cells survive initial treatment by “hibernating,” then reactivate months or years later. This new study shows dormant cells can already be found inside untreated tumors, often shielded by surrounding immune and connective tissue cells.

How was the study done?

Researchers combined single-cell RNA sequencing with spatial transcriptomics to map untreated breast tumors in detail, identifying where dormant cells sit and which cells surround them. The findings are published in the journal Genome Medicine.

Does this change breast cancer treatment now?

No. This is early-stage research that improves understanding of why tumors relapse. It may, however, guide future drug development toward targeting dormant cells and their protective environments, possibly using combination therapies aimed at different tumor regions.

Who conducted the research?

The study was led by researchers from the MRC Laboratory of Medical Sciences (LMS), Imperial College London and the UCL Genetics Institute in the United Kingdom.

Sources: MRC Laboratory of Medical Sciences / ScienceDaily; study published in Genome Medicine (September 2026).